NCT03318809View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 12, 2017

Primary Completion Date

March 12, 2018

Study Completion Date

April 5, 2018

Conditions
Heart Failure
Interventions
DRUG

AMG 986

tablets for oral administration

Trial Locations (4)

32809

Research Site, Orlando

55404

Research Site, Minneapolis

78215

Research Site, San Antonio

92780

Research Site, Tustin

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY